Search Results
Jul 08, 2025, 02:17 ET Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer
and a successful track record in drug development, providing clinical leadership resulting in four product approvals, including in rare disease and gene therapy, and comes with expertise and success in building high-functioning teams, building pipelines and executing clinical development programs across
More news about: Hansa Biopharma AB
Jul 08, 2025, 02:15 ET Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer
and a successful track record in drug development, providing clinical leadership resulting in four product approvals, including in rare disease and gene therapy, and comes with expertise and success in building high-functioning teams, building pipelines and executing clinical development programs across
More news about: Hansa Biopharma AB
Jul 08, 2025, 02:00 ET Independent Meta-Analysis Shows SkylineDx's Merlin CP-GEP Assay Accurately Stratifies Patients for Sentinel Lymph Node Biopsy Selection
prediction model for cutaneous melanoma patients and is the only commercially available GEP test that combines clinicopathologic (CP) variables with gene expression profiling (GEP) into a single integrated algorithm. This CP-GEP model is also the only GEP test that provides a binary stratification of
More news about: SkylineDx
Jul 07, 2025, 20:12 ET SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial
More news about: THE ROSEN LAW FIRM, P. A.
Jul 07, 2025, 17:40 ET SRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Class Period, Sarepta was engaged in the development of therapies to treat Duchenne muscular dystrophy ("Duchenne"), including ELEVIDYS (a prescription gene therapy intended for a limited category of people with Duchenne). The Sarepta Therapeutics class action lawsuit alleges that
More news about: Robbins Geller Rudman & Dowd LLP
Jul 07, 2025, 14:45 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
action] On May 27, 2025, Rocket issued a press release "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease." The press release disclosed that "[a] patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected
More news about: Pomerantz LLP
Jul 07, 2025, 13:58 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
dystrophy ("DMD"), a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused by the mutation of the dystrophin gene, resulting in, inter alia, a limited production of the dystrophin protein, which in turn leads to DMD's clinical features. According to PepGen,
More news about: Pomerantz LLP
Jul 07, 2025, 12:51 ET Pivot Bio Expands Retailer Network Through Partnership with Aurora Cooperative
Pivot Bio PROVEN® 40 and PROVEN® G3, Pivot Bio's second- and third-gen nitrogen-fixing solution for corn, powered by patented gene-edited technology. "Aurora Cooperative is recognized as a leader in the agricultural industry, known for being in the forefront of innovation,
More news about: Pivot Bio, Inc
Jul 07, 2025, 11:34 ET Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)
EKTERLY." About Orsini Providing patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary
More news about: Orsini
Jul 07, 2025, 11:30 ET mRNA Sequencing Market Size to Hit USD 4.02 billion by 2031, Growing at 13.6% CAGR, Benefits from Surging Prevalence of Cancer | The Insight Partners
within a cell or tissue. It provides a complete view of gene expression, including the identification of known and novel transcript isoforms, gene fusions, and allele-specific expression. With its high sensitivity and precision in quantifying gene expression, mRNA sequencing serves as a valuable resource
More news about: The Insight Partners
Jul 07, 2025, 10:44 ET Lutris Pharma Presents Additional Positive Data from Its Phase 2 Trial of LUT014 Gel Demonstrating Significant Efficacy in Treating Acneiform Rash Associated with Use of Anti-EGFR Cancer Therapies at the ESMO Gastrointestinal Cancers Congress 2025
pathway is one of the key pathways that regulate growth, survival, proliferation, and differentiation of cells. B-Raf is a protein encoded by the BRAF gene and is a downstream effector component of the EGFR signaling pathway. EGFR has been shown to be over-activated in various human cancers, including colorectal,
More news about: Lutris Pharma
Jul 07, 2025, 10:32 ET Lutris Pharma Presents Additional Positive Data from Its Phase 2 Trial of LUT014 Gel Demonstrating Significant Efficacy in Treating Acneiform Rash Associated with Use of Anti-EGFR Cancer Therapies at the ESMO Gastrointestinal Cancers Congress 2025
pathway is one of the key pathways that regulate growth, survival, proliferation, and differentiation of cells. B-Raf is a protein encoded by the BRAF gene and is a downstream effector component of the EGFR signaling pathway. EGFR has been shown to be over-activated in various human cancers, including colorectal,
More news about: Lutris Pharma
Jul 07, 2025, 10:31 ET World-Class, Turnkey Cro Facility Available Through Bankruptcy Sale with Full Suite of Lab Equipment & Intellectual Property
in funding, quickly established itself as a leader in advanced therapy development. The company specialized in cutting-edge technologies, including gene editing, mRNA and T cell-based therapies and operated state-of-the-art facilities in both Ohio and California.
More news about: Hilco Global
Jul 07, 2025, 09:00 ET August 25, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against SRPT
during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: The Gross Law Firm
Jul 07, 2025, 08:30 ET VIOME COLLABORATES WITH MICROSOFT TO DELIVER PREVENTIVE HEALTHCARE WITH ONE OF WORLD'S LARGEST RNA DATASETS
As part of this collaboration, Viome will integrate its dataset of human and microbial gene expression, along with its cutting-edge bioinformatics and AI-powered recommendation engine, with Microsoft Azure infrastructure services, including
More news about: Viome Life Sciences
Jul 07, 2025, 08:30 ET European Medicines Agency Grants Orphan Drug Designation to Spinogenix's SPG601 for Treatment of Fragile X Syndrome (FXS)
medicine. FXS, a known cause of autism, is the leading inherited form of intellectual disability caused by the silencing of the Fmr1 gene. FXS can produce a wide range of disabling symptoms, with many individuals requiring lifelong around-the-clock supportive care. SPG601 works
More news about: Spinogenix
Jul 07, 2025, 08:12 ET National Heart, Lung, and Blood Institute / National Institutes of Health Signs Clinical Trial Agreement with Vascarta Inc. to Perform Phase 1 Clinical Study of VAS-101 in Sickle Cell Disease
cell disease in the USA is more than 20 years shorter than the average expected lifespan. SCD is caused by a single point mutation in the globin gene leading to sickling of red blood cells. It is characterized by severe pain, inflammation, oxidative stress, and organ damage, which contributes to the
More news about: Vascarta Inc
Jul 07, 2025, 04:04 ET INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
INFORMATION Allegations in the Complaint Sarepta is a biopharmaceutical company focused on genetic medicine, including its gene therapy product ELEVIDYS, developed for the treatment of Duchenne muscular dystrophy. According to the filed complaint, during the Class Period,
More news about: Wolf Haldenstein Adler Freeman & Herz LLP
Jul 07, 2025, 01:00 ET Nuevocor Strengthens Board with Appointment of Thierry Abribat
Europe. Our unique approach, enabled by our proprietary PrOSIA mechanobiology platform, surpasses the limitations of traditional gene replacement therapy – which treats individual gene mutations – to treating defects in shared disease pathways across multiple cardiomyopathies by addressing the functional root
More news about: Nuevocor
Jul 04, 2025, 11:54 ET DoH, USCF und IGI erkunden die Einrichtung der weltweit ersten Zentren für Genomchirurgie
Die Genomchirurgie ist eine experimentelle medizinische Technik, die darauf abzielt, fehlerhafte Gene in Zellen zu verändern oder zu ersetzen, um Krankheiten zu behandeln oder zu verhindern. Erreicht wird dies durch personalisierte Gentherapien oder
More news about: The Department of Health - Abu Dhabi
Jul 04, 2025, 10:18 ET DoH, USCF and IGI Explore Establishing the World's first-of-their kind Centres for Genome Surgery
Doudna, winner of the 2020 Nobel Prize for CRISPR gene editing, is to make it the standard of medical care, no matter where such a child is born. The IGI's deep partnership with Danaher that made an enabling contribution to the on-demand gene edit earlier this year provides an outstanding technological
More news about: The Department of Health - Abu Dhabi
Jul 04, 2025, 09:46 ET DoH, USCF and IGI Explore Establishing the World's first-of-their kind Centres for Genome Surgery
Doudna, winner of the 2020 Nobel Prize for CRISPR gene editing, is to make it the standard of medical care, no matter where such a child is born. The IGI's deep partnership with Danaher that made an enabling contribution to the on-demand gene edit earlier this year provides an outstanding technological
More news about: The Department of Health - Abu Dhabi
Jul 03, 2025, 14:15 ET RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
[email protected]. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided
More news about: Robbins Geller Rudman & Dowd LLP
Jul 03, 2025, 09:00 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT
during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: The Gross Law Firm
Jul 02, 2025, 15:38 ET SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial
More news about: THE ROSEN LAW FIRM, P. A.